Signify Health Acquires Caravan Health For $250 Million

Signify Health has signed an agreement to acquire Caravan Health, a company that helps hospitals and health systems that have value-based care arrangements. These services include maximizing 340B savings.

Signify Health, a value-based healthcare platform with a network of over 3,000 physician practices and facilities, has signed an agreement to acquire Caravan Health, a company that helps hospitals and health systems with value-based care arrangements maximize 340B savings, the

Read More »

With Planned Series of House Speeches Delayed, GOP Lawmaker Speaks Out in Support of 340B

U.S. Rep Jake LaTurner (R-Kan.) praised 340B on the House floor Tuesday. An hour's worth of other testimonials by House members planned for the same day was postponed.

A Kansas Republican congressman on Tuesday urged fellow House members in a brief floor speech to “reaffirm our commitment to protecting” the 340B program.

Rep. Jake LaTurner (R-Kan.) congratulated 340B on its 30th anniversary. He said the program “has helped

Read More »

Democratic Senator’s Illness Stalls Action on Drug Pricing Indefinitely

Sen. Ben Ray Lujan's (D-N.M.) recent stroke and absence makes it even less likely that Congress will pass Democratic drug pricing legislation any time soon.

Prospects for passage of Democratic drug pricing legislation as part of the Build Back Better (BBB) Act dimmed again last week with news that Sen. Ben Ray Lujan (D-N.M.) had a stroke on Jan 27.

Lujan’s chief of staff

Read More »

ICER Says Four Drugs Are Cost-Effective in Keeping COVID-19 Patients Out of Hospitals

The Institute for Clinical and Economic Review has tentatively concluded that four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients.

The Institute for Clinical and Economic Review (ICER) has issued a draft report concluding four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients. The independent nonprofit group evaluates prescription drugs and medical treatments’ cost effectiveness

Read More »

Scholarship Created in Memory of Long-Time 340B Leader Carl Taylor

The Carl Taylor Pharmacy Administration Scholarship at the University of North Carolina (UNC) Eshelman School of Pharmacy was announced this morning at the 340B Coalition Winter Conference in San Diego. Taylor, 76, the longtime pharmacy director at Piedmont Health Services in Chapel Hill, N.C., died last Sept. 24.

An endowed scholarship at the University of North Carolina (UNC) Eshelman School of Pharmacy has been established in memory of Carl Taylor, the longtime pharmacy director at Piedmont Health Services in Chapel Hill, N.C. Taylor, age 76, died last Sept.

Read More »

“Pharma Bro” Who Drew Ire of 340B Providers and Drug Industry Alike Barred from Pharmaceutical Industry for Life

A federal district judge imposed a lifetime ban against Martin Shkreli participating in the pharmaceutical industry and ordered him to pay $64.6 million to offset ill-gotten gains, stemming from his company's purchase of and huge price hike on the drug Daraprim.

A federal district judge on Friday held “pharma bro” Martin Shkreli liable for antitrust claims brought by the Federal Trade Commission (FTC) and seven states.

U.S. Senior District Judge Denise Cote of the Southern District of New York imposed a

Read More »

In Big Win for Pharmacy Groups, CMS Proposes Significant Changes to Medicare Part D Clawbacks

CMS wants to change Medicare Part D rules to rein in PBMs' controversial practice of clawing back drug payments to pharmacies after point of sale.

The Centers for Medicare & Medicaid Services (CMS) yesterday proposed changing Medicare Part D rules to curb plan sponsors and pharmacy benefit managers’ skyrocketing use of direct and indirect renumeration fees (DIR)—PBMs’ controversial practice of clawing back drug payments to

Read More »

Judge Denies Calif. 340B Health Centers’ Motion to Halt State Medicaid Drug Payment Change

California health centers say they will continue to fight against the transfer of state Medicaid managed care drug coverage to Medicaid fee for service, despite being denied a temporary restraining order against the change.

A federal judge in Sacramento, Calif., late yesterday declined to stop California Medicaid’s transfer of managed care drug coverage to Medicaid fee for service that took effect on Jan. 1. Health centers enrolled in the 340B drug pricing program pledged

Read More »

California Asks Judge to Reject 340B Community Health Centers’ Request to Stop Medicaid Drug Payment Change

California's state health department asked a judge yesterday to reject 340B community health centers' request to halt a major state Medicaid drug reimbursement change that began on Jan. 1.

Federally qualified health clinics in California have no right to sue to stop a major state Medicaid drug reimbursement change that began on Jan. 1., the state Department of Health Care Services (DHCS) argued in a legal brief filed Wednesday.

Read More »

Three Big Predictions for the 340B Program in 2022

340B Report Publisher and Chief Executive Officer Ted Slafsky makes three big predictions for the 340B program for 2022 in his latest monthly column for Omnicell’s blog.

In his monthly column for Omnicell’s blog, 340B Report Publisher and Chief Executive Officer Ted Slafsky makes three big predictions for the 340B program for 2022. They focus on:

  • the U.S. Supreme Court case on Medicare reimbursement to 340B hospitals
  • where
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report